The Bidirectional Relationship of Cancer and Hemostasis and the Potential Role of Anticoagulant Therapy in Moderating Thrombosis and Cancer Spread

ABSTRACT

The relationship between hemostasis and malignancy is well recognized, with both elements interacting in a “vicious cycle” where cancers overexpress procoagulants and thrombin, which in turn promote both prothrombotic potential and tumor growth, invasion, and spread. Indeed, venous thromboembolism, particularly idiopathic venous thrombosis, occurs frequently as a paraneoplastic phenomenon, and in turn several components of primary and secondary hemostasis (namely platelets, tissue factor, and thrombin) play an important role in primary tumor growth and metastasization. Despite the many and various mechanisms involved in this multifaceted relationship, anticoagulants might represent an attractive anticancer therapy, in that current research supports the hypothesis that such drugs may offer a better control of cancer progression. The main biological and clinical evidence on the relationship between cancer and hemostasis are briefly summarized in this review, as is the potential benefits of anticoagulant therapy in this setting.

KEYWORDS

Cancer - hemostasis - anticoagulant therapy

REFERENCES

• 1 De Bouillaud S. L'oblitération des veines et de son influence sur la formation des hydropisies partielles: considération sur la hydropisies passive et général.  Arch Gen Med. 1823;  1 188-204
• 2 Trousseau A. Phlegmasia alba dolens. In: Trousseau A Clinique médicinale de l'Hôtel-Dieu de Paris. Paris, France; JB Bailliere et fils 1865: 645-712
• 3 Otten H M, Prins M H. Venous thromboembolism and occult malignancy.  Thromb Res. 2001;  102 V187-194
• 4 Nierodzik M L, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.  J Clin Invest. 1991;  87(1) 229-236
• 5 Buller H R, van Doormaal F F, van Sluis G L, Kamphuisen P W. Cancer and thrombosis: from molecular mechanisms to clinical presentations.  J Thromb Haemost. 2007;  5(Suppl 1) 246-254
• 6 Tsopanoglou N E, Maragoudakis M E. Role of thrombin in angiogenesis and tumor progression.  Semin Thromb Hemost. 2004;  30(1) 63-69
• 7 Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis.  Blood. 2004;  104(9) 2746-2751
• 8 Zain J, Huang Y Q, Feng X, Nierodzik M L, Li J J, Karpatkin S. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.  Blood. 2000;  95(10) 3133-3138
• 9 Versteeg H H, Ruf W. Emerging insights in tissue factor-dependent signaling events.  Semin Thromb Hemost. 2006;  32(1) 24-32
• 10 Østerud B, Bjørklid E. Sources of tissue factor.  Semin Thromb Hemost. 2006;  32(1) 11-23
• 11 Rao L V. Tissue factor as a tumor procoagulant.  Cancer Metastasis Rev. 1992;  11(3-4) 249-266
• 12 Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy.  Semin Thromb Hemost. 2006;  32(1) 54-70
• 13 Kataoka H, Uchino H, Asada Y et al.. Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver.  Int J Cancer. 1997;  72(5) 878-884
• 14 Signaevsky M, Hobbs J, Doll J, Liu N, Soff G A. Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis.  Semin Thromb Hemost. 2008;  34(2) 161-169
• 15 Zwicker J I. Tissue factor-bearing microparticles and cancer.  Semin Thromb Hemost. 2008;  34(2) 195-198
• 16 Milsom C, Yu J, May L, Magnus N, Rak J. Diverse roles of tissue factor-expressing cell subsets in tumor progression.  Semin Thromb Hemost. 2008;  34(2) 170-181
• 17 Falanga A, Barbui T, Rickles F R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.  Semin Thromb Hemost. 2008;  34(2) 204-210
• 18 Zhang Y, Deng Y, Luther T et al.. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.  J Clin Invest. 1994;  94(3) 1320-1327
• 19 Rickles F R, Patierno S, Fernandez P M. Tissue factor, thrombin, and cancer.  Chest. 2003;  124(3, Suppl) 58S-68S
• 20 Ruf W, Mueller B M. Tissue factor in cancer angiogenesis and metastasis.  Curr Opin Hematol. 1996;  3(5) 379-384
• 21 Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer.  J Thromb Thrombolysis. 2007;  24(1) 29-38
• 22 Yu J, May L, Milsom C et al.. Contribution of host-derived tissue factor to tumor neovascularization.  Arterioscler Thromb Vasc Biol. 2008;  28(11) 1975-1981
• 23 Amirkhosravi A, Amaya M, Desai H, Francis J L. Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity.  Blood Coagul Fibrinolysis. 2002;  13(6) 505-512
• 24 Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer.  Semin Thromb Hemost. 2008;  34(2) 147-153
• 25 Palumbo J S, Talmage K E, Massari J V et al.. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.  Blood. 2007;  110(1) 133-141
• 26 Hembrough T A, Swartz G M, Papathanassiu A et al.. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.  Cancer Res. 2003;  63(11) 2997-3000
• 27 Ngo C V, Picha K, McCabe F et al.. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models.  Int J Cancer. 2007;  120(6) 1261-1267
• 28 Versteeg H H, Schaffner F, Kerver M et al.. Inhibition of tissue factor signaling suppresses tumor growth.  Blood. 2008;  111(1) 190-199
• 29 Amarzguioui M, Peng Q, Wiiger M T et al.. Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells.  Clin Cancer Res. 2006;  12(13) 4055-4061
• 30 Kondraganti S, Gondi C S, Gujrati M et al.. Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.  Int J Oncol. 2006;  29(1) 25-32
• 31 Borsig L. The role of platelet activation in tumor metastasis.  Expert Rev Anticancer Ther. 2008;  8(8) 1247-1255
• 32 Sierko E, Wojtukiewicz M Z. Inhibition of platelet function: does it offer a chance of better cancer progression control?.  Semin Thromb Hemost. 2007;  33(7) 712-721
• 33 Enjeti A K, Lincz L F, Seldon M. Microparticles in health and disease.  Semin Thromb Hemost. 2008;  34(7) 683-691
• 34 Toth B, Liebhardt S, Steinig K et al.. Platelet-derived microparticles and coagulation activation in breast cancer patients.  Thromb Haemost. 2008;  100(4) 663-669
• 35 Sierko E, Wojtukiewicz M Z. Platelets and angiogenesis in malignancy.  Semin Thromb Hemost. 2004;  30(1) 95-108
• 36 McNicol A, Israels S J. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection.  Cardiovasc Hematol Disord Drug Targets. 2008;  8(2) 99-117
• 37 Chen M, Geng J G. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis.  Arch Immunol Ther Exp (Warsz). 2006;  54(2) 75-84
• 38 Lowenstein C J, Morrell C N, Yamakuchi M. Regulation of Weibel-Palade body exocytosis.  Trends Cardiovasc Med. 2005;  15(8) 302-308
• 39 Vestweber D, Blanks J E. Mechanisms that regulate the function of the selectins and their ligands.  Physiol Rev. 1999;  79(1) 181-213
• 40 Kim Y J, Borsig L, Han H L, Varki N M, Varki A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium.  Am J Pathol. 1999;  155(2) 461-472
• 41 Borsig L, Wong R, Feramisco J, Nadeau D R, Varki N M, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.  Proc Natl Acad Sci U S A. 2001;  98(6) 3352-3357
• 42 Robak P, Smolewski P, Robak T. The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies.  Leuk Lymphoma. 2008;  49(8) 1452-1462
• 43 Kast R E. Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.  Med Oncol. 2007;  24(1) 1-6
• 44 Smith C J, McKay G A, Fisher M. Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.  Int J Clin Pract. 2008;  62(5) 810-815
• 45 Hart A R, Kennedy H, Harvey I. Pancreatic cancer: a review of the evidence on causation.  Clin Gastroenterol Hepatol. 2008;  6(3) 275-282
• 46 Agrawal A, Fentiman I S. NSAIDs and breast cancer: a possible prevention and treatment strategy.  Int J Clin Pract. 2008;  62(3) 444-449
• 47 Harris R E. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.  Subcell Biochem. 2007;  42 93-126
• 48 Jana N R. NSAIDs and apoptosis.  Cell Mol Life Sci. 2008;  65(9) 1295-1301
• 49 Shureiqi I, Chen D, Lee J J et al.. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells.  J Natl Cancer Inst. 2000;  92(14) 1136-1142
• 50 Ulrich C M, Bigler J, Potter J D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics.  Nat Rev Cancer. 2006;  6(2) 130-140
• 51 Palumbo J S, Talmage K E, Massari J V et al.. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells.  Blood. 2005;  105(1) 178-185
• 52 Pietras K, Sjöblom T, Rubin K, Heldin C H, Ostman A. PDGF receptors as cancer drug targets.  Cancer Cell. 2003;  3(5) 439-443
• 53 Östman A, Heldin C H. Involvement of platelet-derived growth factor in disease: development of specific antagonists.  Adv Cancer Res. 2001;  80 1-38
• 54 Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.  Nat Rev Drug Discov. 2002;  1(7) 493-502
• 55 Baranowska-Kortylewicz J, Abe M, Nearman J, Enke C A. Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer.  Clin Cancer Res. 2007;  13(1) 299-306
• 56 Wu W B, Chiang H S, Fang J Y, Hung C F. Inhibitory effect of lycopene on PDGF-BB-induced signalling and migration in human dermal fibroblasts: a possible target for cancer.  Biochem Soc Trans. 2007;  35(Pt 5) 1377-1378
• 57 Felding-Habermann B, O'Toole T E, Smith J W et al.. Integrin activation controls metastasis in human breast cancer.  Proc Natl Acad Sci U S A. 2001;  98(4) 1853-1858
• 58 Mehta P, Lawson D, Ward M B, Lee-Ambrose L, Kimura A. Effects of thromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation.  Cancer Res. 1986;  46(10) 5061-5063
• 59 Nelson R M, Cecconi O, Roberts W G, Aruffo A, Linhardt R J, Bevilacqua M P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation.  Blood. 1993;  82(11) 3253-3258
• 60 Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.  J Clin Invest. 1998;  101(4) 877-889
• 61 Ludwig R J, Boehme B, Podda M et al.. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis.  Cancer Res. 2004;  64(8) 2743-2750
• 62 Hostettler N, Naggi A, Torri G et al.. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.  FASEB J. 2007;  21(13) 3562-3572
• 63 Lee D Y, Park K, Kim S K et al.. Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.  Clin Cancer Res. 2008;  14(9) 2841-2849
• 64 Lippi G, Franchini M, Guidi G C. Diagnostic approach to inherited bleeding disorders.  Clin Chem Lab Med. 2007;  45(1) 2-12
• 65 Ruf W, Mueller B M. Thrombin generation and the pathogenesis of cancer.  Semin Thromb Hemost. 2006;  32(Suppl 1) 61-68
• 66 O'Reilly M S. Antiangiogenic antithrombin.  Semin Thromb Hemost. 2007;  33(7) 660-666
• 67 Huang Y Q, Li J J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes.  Thromb Haemost. 2001;  86(4) 1094-1098
• 68 Wang J, Morita I, Onodera M, Murota S I. Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide.  J Cell Physiol. 2002;  190(2) 238-250
• 69 Caunt M, Hu L, Tang T, Brooks P C, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.  Cancer Res. 2006;  66(8) 4125-4132
• 70 Huang Y Q, Li J J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells.  Blood. 2002;  99(5) 1646-1650
• 71 Duhamel-Clérin E, Orvain C, Lanza F, Cazenave J P, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells.  Arterioscler Thromb Vasc Biol. 1997;  17(10) 1931-1938
• 72 Hu L, Roth J M, Brooks P, Luty J, Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis.  Cancer Res. 2008;  68(12) 4666-4673
• 73 Snyder K M, Kessler C M. The pivotal role of thrombin in cancer biology and tumorigenesis.  Semin Thromb Hemost. 2008;  34(8) 734-741
• 74 Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination.  Semin Thromb Hemost. 2007;  33(7) 688-694
• 75 Mousa S A. Anti-thrombotics in thrombosis and cancer.  Future Oncol. 2005;  1(3) 395-403
• 76 Smorenburg S M, Van Noorden C J. The complex effects of heparins on cancer progression and metastasis in experimental studies.  Pharmacol Rev. 2001;  53(1) 93-105
• 77 Bobek V, Kovarík J. Antitumor and antimetastatic effect of warfarin and heparins.  Biomed Pharmacother. 2004;  58(4) 213-219
• 78 Guo R R, Liu Y, Lu W L et al.. A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma.  Biol Pharm Bull. 2008;  31(4) 696-702
• 79 Weitz I C, Liebman H A. The role of oral anticoagulants in tumor biology.  Semin Thromb Hemost. 2007;  33(7) 695-698
• 80 Sciumbata T, Caretto P, Pirovano P et al.. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival.  Invasion Metastasis. 1996;  16(3) 132-143
• 81 Onaran I, Sencan S, Demirtaş H, Aydemir B, Ulutin T, Okutan M. Toxic-dose warfarin-induced apoptosis and its enhancement by gamma ionizing radiation in leukemia K562 and HL-60 cells is not mediated by induction of oxidative stress.  Naunyn Schmiedebergs Arch Pharmacol. 2008;  378(5) 471-481
• 82 Association of Surgeons of Great Britain and Ireland Annual Meeting. Glasgow, United Kingdom, 13–15 April 2005. Abstracts.  Br J Surg. 2005;  92(Suppl 1) 1-159
• 83 Franchini M, Tagliaferri A, Mannucci P M. The management of hemophilia in elderly patients.  Clin Interv Aging. 2007;  2(3) 361-368
• 84 Walker I R, Julian J A. Association of Hemophilia Clinic Directors of Canada . Causes of death in Canadians with haemophilia 1980–1995.  Haemophilia. 1998;  4(5) 714-720
• 85 Darby S C, Kan S W, Spooner R J et al.. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.  Blood. 2007;  110(3) 815-825
• 86 Brüggemann L W, Versteeg H H, Niers T M, Reitsma P H, Spek C A. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders.  J Cell Mol Med. 2008;  12(6B) 2622-2627
• 87 Langer F, Amirkhosravi A, Ingersoll S B et al.. Experimental metastasis and primary tumor growth in mice with hemophilia A.  J Thromb Haemost. 2006;  4 1056-1062
• 88 Lee A Y. The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer.  Thromb Res. 2007;  120(Suppl 2) S121-S127
• 89 Lemoine N R. Antithrombotic therapy in cancer.  J Clin Oncol. 2005;  23(10) 2119-2120
• 90 Falanga A. The effect of anticoagulant drugs on cancer.  J Thromb Haemost. 2004;  2(8) 1263-1265
• 91 Tagalakis V, Blostein M, Robinson-Cohen C, Kahn S R. The effect of anticoagulants on cancer risk and survival: systematic review.  Cancer Treat Rev. 2007;  33(4) 358-368
• 92 Zacharski L R, Henderson W G, Rickles F R et al.. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75.  JAMA. 1981;  245(8) 831-835
• 93 Smorenburg S M, Vink R, Otten H M, Swaneveld F, Büller H R. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis.  Thromb Haemost. 2001;  86(6) 1586-1587
• 94 Kakkar A K, Hedges A R, Williamson R CN et al.. Perioperative heparin therapy inhibits late deaths from metastatic cancer.  Int J Oncol. 1995;  6 885-888
• 95 Lebeau B, Chastang C, Brechot J M et al.. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group.  Cancer. 1994;  74(1) 38-45
• 96 Altinbas M, Coskun H S, Er O et al.. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.  J Thromb Haemost. 2004;  2(8) 1266-1271
• 97 Smorenburg S M, Hettiarachchi R J, Vink R, Büller H R. The effects of unfractionated heparin on survival in patients with malignancy—a systematic review.  Thromb Haemost. 1999;  82(6) 1600-1604
• 98 Kakkar A K, Levine M N, Kadziola Z et al.. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS).  J Clin Oncol. 2004;  22(10) 1944-1948
• 99 Klerk C P, Smorenburg S M, Otten H M et al.. The effect of low molecular weight heparin on survival in patients with advanced malignancy.  J Clin Oncol. 2005;  23(10) 2130-2135
• 100 Lee A Y, Rickles F R, Julian J A et al.. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.  J Clin Oncol. 2005;  23(10) 2123-2129
• 101 Lazo-Langner A, Goss G D, Spaans J N, Rodger M A. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials.  J Thromb Haemost. 2007;  5(4) 729-737
• 102 Sandler R S, Halabi S, Baron J A et al.. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.  N Engl J Med. 2003;  348(10) 883-890
• 103 Baron J A, Cole B F, Sandler R S et al.. A randomized trial of aspirin to prevent colorectal adenomas.  N Engl J Med. 2003;  348(10) 891-899
• 104 Bertagnolli M M, Eagle C J, Zauber A G APC Study Investigators et al. Celecoxib for the prevention of sporadic colorectal adenomas.  N Engl J Med. 2006;  355(9) 873-884
• 105 Baron J A, Sandler R S, Bresalier R S APPROVe Trial Investigators et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.  Gastroenterology. 2006;  131(6) 1674-1682
• 106 Thun M J, Henley S J, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.  J Natl Cancer Inst. 2002;  94(4) 252-266
• 107 Chan A T, Ogino S, Fuchs C S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.  N Engl J Med. 2007;  356(21) 2131-2142
• 108 Hejna M, Raderer M, Zielinski C C. Inhibition of metastases by anticoagulants.  J Natl Cancer Inst. 1999;  91(1) 22-36
• 109 Franchini M, Lippi G. Antagonists of activated factor X and thrombin: innovative antithrombotic agents.  Curr Vasc Pharmacol. 2007;  5(2) 121-128
• 110 Harenberg J. Development of new anticoagulants: present and future.  Semin Thromb Hemost. 2008;  34(8) 779-793